{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:40:22Z","timestamp":1756374022737,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,5,6]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Graft-versus-host disease (GvHD) is a potentially life-threatening and commonly encountered event of allogeneic haematopoietic stem cell transplantation. Here, we present a young adult male with primary refractory Hodgkin\u2019s lymphoma who received a transplant and developed cutaneous GvHD after donor lymphocyte infusion, which was managed with cyclosporine and steroids. However, while the patient was under immunosuppressive treatment, diffuse confluent whitish patches on the patient\u2019s tongue were observed. A biopsy of the tongue lesions revealed lichenoid, hyperkeratotic tissue changes and intraepithelial T-cell infiltration consistent with chronic GvHD. He was treated with mycophenolate mofetil for 6 months with minimal improvement. Janus-associated kinase inhibitor (ruxolitinib) treatment was commenced, with complete resolution of the tongue lesions and treatment discontinuation 5 months later. Currently, 5 years after allogeneic transplantation, he is in remission and does not need immunosuppressive therapy.<\/jats:p>","DOI":"10.1136\/bcr-2021-247888","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T13:57:32Z","timestamp":1653314252000},"page":"e247888","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Tongue graft-versus-host disease: remission with ruxolitinib"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-1928","authenticated-orcid":false,"given":"Katerina","family":"Grafanaki","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital of Patras, School of Medicine, Patras, Rion, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Lygeros","sequence":"additional","affiliation":[{"name":"Ear, Nose, Throat Department, University General Hospital of Patras, Patras, Rion, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Department of Internal Medicine, University Hospital of Patras, Rion, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Liga","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Department of Internal Medicine, University Hospital of Patras, Rion, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"2025082802025337000_15.5.e247888.1","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.bbmt.2017.12.797","article-title":"The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia","volume":"24","author":"Schroeder","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025082802025337000_15.5.e247888.2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.858.858","article-title":"Treatment of corticosteroid-refractory graft-versus-host disease with ruxolitinib in 95 patients","volume":"126","author":"Zeiser","year":"2015","journal-title":"Blood"},{"key":"2025082802025337000_15.5.e247888.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004"},{"key":"2025082802025337000_15.5.e247888.4","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.308"},{"key":"2025082802025337000_15.5.e247888.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.07.021"},{"key":"2025082802025337000_15.5.e247888.6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/bmt.2016.272","article-title":"Low dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia","volume":"52","author":"Tsirigotis","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2025082802025337000_15.5.e247888.7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/idj.12584","article-title":"Oral graft-versus-host disease: a pictorial review and a guide for dental practitioners","volume":"71","author":"Elad","year":"2021","journal-title":"Int Dent J"},{"key":"2025082802025337000_15.5.e247888.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"2025082802025337000_15.5.e247888.9","first-page":"4121","article-title":"Oral chronic GVHD after allogeneic stem cell transplantation without total body irradiation performed at a young age","volume":"30","author":"Tanem","year":"2022","journal-title":"Support Care Cancer"},{"key":"2025082802025337000_15.5.e247888.10","doi-asserted-by":"crossref","DOI":"10.1093\/jncimonographs\/lgz007","article-title":"Oral complications of chronic graft-versus-host disease","volume":"2019","author":"Fall-Dickson","year":"2019","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2025082802025337000_15.5.e247888.11","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.bbmt.2016.08.020","article-title":"An open-label phase II randomized trial of topical dexamethasone and tacrolimus solutions for the treatment of oral chronic graft-versus-host disease","volume":"22","author":"Treister","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025082802025337000_15.5.e247888.12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.adaj.2020.08.001","article-title":"Oral chronic graft-versus-host disease: what the general dental practitioner needs to know","volume":"151","author":"Haverman","year":"2020","journal-title":"J Am Dent Assoc"},{"key":"2025082802025337000_15.5.e247888.13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"2025082802025337000_15.5.e247888.14","unstructured":"FDA approves ruxolitinib for chronic graft-versus-host disease [Internet]. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ruxolitinib-chronic-graft-versus-host-disease [Accessed 20 Oct 2021]."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-247888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:03:05Z","timestamp":1756371785000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-247888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,23]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/bcr-2021-247888"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-247888","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}